Drugs /

mk-4830

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
A human monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; LILRB2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ILT4 monoclonal antibody MK-4830 targets and binds to ILT4. This prevents the binding of ILT4 ligands to their receptor and prevents ILT4-mediated signaling. This abrogates the immunosuppressive activities of ILT4 in the tumor microenvironment (TME), activates the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. ILT4, plays a key role in tumor immune evasion. ILT4, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and certain tumor cells.

Clinical Trials

View Clinical Trials for mk-4830

Mk-4830 has been investigated in 6 clinical trials, of which 6 are open and 0 are closed. Of the trials investigating mk-4830, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open).

Deficient DNA Mismatch Repair (dMMR), ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for mk-4830 clinical trials.

Non-small cell lung carcinoma, clear cell renal cell carcinoma, and small cell lung carcinoma are the most common diseases being investigated in mk-4830 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mk-4830
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mk-4830 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-leukocyte immunoglobulin-like receptor 2 monoclonal antibody mk-4830, mk4830, mk 4830, anti-lir2 monoclonal antibody mk-4830, anti-ilt4 monoclonal antibody mk-4830
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
LILRB2
NCIT ID [1]:
C160204

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.